- Home
- ADPT vs BBT Comparison
ADPT vs BBT Comparison
Compare ADPT & BBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADPT | BBT |
|---|---|---|
| Founded | 2009 | 1846 |
| Country | United States | United States |
| Employees | N/A | 2050 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADPT | BBT |
|---|---|---|
| Price | $14.08 | $31.20 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | $17.78 | ★ $33.25 |
| AVG Volume (30 Days) | ★ 1.8M | 603.5K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 4.07% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | $77.88 |
| Revenue Next Year | $22.72 | $4.31 |
| P/E Ratio | ★ N/A | $29.98 |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $7.16 | $22.81 |
| 52 Week High | $20.76 | $32.83 |
Technical Indicators
Market Signals| Indicator | ADPT | BBT |
|---|---|---|
| Relative Strength Index (RSI) | 49.32 | 52.55 |
| Support Level | $12.22 | $29.17 |
| Resistance Level | $17.52 | $32.09 |
| Average True Range (ATR) | 0.84 | 0.66 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 54.11 | 32.37 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
About BBT Beacon Financial Corporation
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.